These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 19508663

  • 1. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
    Schwander B, Gradl B, Zöllner Y, Lindgren P, Diener HC, Lüders S, Schrader J, Villar FA, Greiner W, Jönsson B.
    Value Health; 2009 Sep; 12(6):857-71. PubMed ID: 19508663
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Eprosartan: a review of its use in hypertension.
    Plosker GL.
    Drugs; 2009 Sep; 69(17):2477-99. PubMed ID: 19911859
    [Abstract] [Full Text] [Related]

  • 4. Eprosartan in secondary prevention of stroke: the economic evidence.
    Wessels F.
    Cardiovasc J Afr; 2007 Sep; 18(2):95-6. PubMed ID: 17497046
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
    Dowlatshahi D, Hill MD.
    Expert Rev Cardiovasc Ther; 2009 May; 7(5):459-64. PubMed ID: 19419253
    [Abstract] [Full Text] [Related]

  • 7. Preventing cerebrovascular and cardiovascular events after stroke: eprosartan or nitrendipine?
    Johnston SC.
    Nat Clin Pract Neurol; 2006 Jan; 2(1):24-5. PubMed ID: 16932517
    [No Abstract] [Full Text] [Related]

  • 8. Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine?
    Larsen K, Hornnes N, Boysen G.
    Stroke; 2006 Jun; 37(6):1357; author reply 1358. PubMed ID: 16645128
    [No Abstract] [Full Text] [Related]

  • 9. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
    Delles C, Jacobi J, John S, Fleischmann I, Schmieder RE.
    Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
    [Abstract] [Full Text] [Related]

  • 10. Morbidity and mortality on combination versus monotherapy: a posthoc analysis of the Systolic Hypertension in Europe trial.
    Thijs L, Richart T, de Leeuw PW, Kuznetsova T, Grodzicki T, Kawecka-Jaszcz K, O'Brien E, Redón J, Birkenhäger WH, Fagard R, Staessen JA.
    J Hypertens; 2010 Apr; 28(4):865-74. PubMed ID: 20051905
    [Abstract] [Full Text] [Related]

  • 11. Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis.
    Littlewood KJ, Greiner W, Baum D, Zoellner Y.
    BMC Nephrol; 2007 Jul 24; 8():9. PubMed ID: 17645811
    [Abstract] [Full Text] [Related]

  • 12. Eprosartan (Teveten) offers new opportunities to prevent a second stroke.
    Cardiovasc J S Afr; 2005 Jul 24; 16(1):56. PubMed ID: 15778775
    [No Abstract] [Full Text] [Related]

  • 13. Antihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trials.
    Xu FY, Yang B, Shi D, Li H, Zou Z, Shi XY.
    Eur J Clin Pharmacol; 2012 Feb 24; 68(2):195-205. PubMed ID: 21881888
    [Abstract] [Full Text] [Related]

  • 14. Effects of eprosartan on target organ protection.
    de la Sierra A.
    Vasc Health Risk Manag; 2006 Feb 24; 2(1):79-85. PubMed ID: 17319472
    [Abstract] [Full Text] [Related]

  • 15. A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension.
    Leu HB, Charng MJ, Ding PY.
    Jpn Heart J; 2004 Jul 24; 45(4):623-35. PubMed ID: 15353873
    [Abstract] [Full Text] [Related]

  • 16. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
    Shlyakhto E.
    Curr Med Res Opin; 2007 Nov 24; 23 Suppl 5():S13-8. PubMed ID: 18093409
    [Abstract] [Full Text] [Related]

  • 17. Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
    Rupp H.
    Curr Med Res Opin; 2007 Nov 24; 23 Suppl 5():S25-9. PubMed ID: 18093411
    [Abstract] [Full Text] [Related]

  • 18. [AII antagonists in the treatment of hypertension and prevention of CVA].
    Spinar J, Vitovec J.
    Vnitr Lek; 2013 Jan 24; 59(1):71-8. PubMed ID: 23565527
    [Abstract] [Full Text] [Related]

  • 19. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group.
    Elliott WJ.
    J Hum Hypertens; 1999 Jun 24; 13(6):413-7. PubMed ID: 10408592
    [Abstract] [Full Text] [Related]

  • 20. Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
    Argenziano L, Trimarco B.
    Curr Med Res Opin; 1999 Jun 24; 15(1):9-14. PubMed ID: 10216806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.